Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.

CPX - 351 和 midostaurin 联合治疗 FLT3 突变的继发性急性髓系白血病患者 ： 三例并文献复习。

• 影响指数: 8.615
• 发表时间: 08 2020
• 来源期刊: Br J Haematol
• DOI: 10.1111/bjh.16800
• PMID: 32567045
• 文章类型: Case Reports
• 中科院分区: Q1
• 方向: 医学
• 作者列表: Andrews C,Maze D,Murphy T,Sibai H

关键词: AML; CPX-351; FLT3 inhibitors; combination therapies; novel therapies

Mesh: Aged; Allografts; Anemia, Refractory, with Excess of Blasts / physiopathology; Aniline Compounds / administration & dosage; Antineoplastic Combined Chemotherapy Protocols / therapeutic use; Azacitidine / administration & dosage; Breast Neoplasms / radiotherapy surgery; Bridged Bicyclo Compounds, Heterocyclic / administration & dosage; Clinical Trials, Phase III as Topic; Cytarabine / administration & dosage; Daunorubicin / administration & dosage; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute / drug therapy etiology genetics pathology; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes / physiopathology; Neoplasm, Residual; Neoplasms, Radiation-Induced / drug therapy genetics mortality pathology; Oncogene Proteins, Fusion / antagonists & inhibitors genetics; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors / administration & dosage; Pyrazines / administration & dosage; Remission Induction; Salvage Therapy; Staurosporine / administration & dosage analogs & derivatives; Sulfonamides / administration & dosage; fms-Like Tyrosine Kinase 3 / antagonists & inhibitors genetics

Abstract

NUUL